Literature DB >> 15759318

Differential protein expression in human gliomas and molecular insights.

Vaibhav C Chumbalkar1, Chanumolu Subhashini, Vishnu M Dhople, Curam S Sundaram, Medicharla V Jagannadham, Kafnam N Kumar, Pasumarti N B S Srinivas, Ravinutala Mythili, Mulla K Rao, Mahesh J Kulkarni, Sridevi Hegde, Alangar S Hegde, Cini Samual, Vani Santosh, Lalji Singh, Ravi Sirdeshmukh.   

Abstract

Gliomas are the most common of the primary intracranial tumors with astrocytomas constituting about 40%. Using clinically and histologically assessed astrocytomas, we have studied their protein profiles using a two-dimensional gel electrophoresis-mass spectrometry approach and identified differentially expressed proteins which may be useful molecular indicators to understand these tumors. Examination of the protein profiles of 27 astrocytoma samples of different grades revealed 72 distinct, differentially expressed proteins belonging to various functional groups such as cytoskeleton and intermediate filament proteins, heat shock proteins (HSPs), enzymes and regulatory proteins. Based on the consistency of their differential expression, 29 distinct proteins could be short-listed and may have a role in the pathology of astrocytomas. Some were found to be differentially expressed in both Grade III and IV astrocytomas while others were associated with a particular grade. A notable observation was underexpression of Prohibitin, a potential tumor suppressor protein, Rho-GDP dissociation inhibitor, Rho-GDI, a regulator of Rho GTPases and HSPs as well as destabilization of glial fibrillary acidic protein, GFAP, major protein of the glial filaments, in Grade III malignant tumors. We attempt to explain glioma malignancy and progression in terms of their combined role.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15759318     DOI: 10.1002/pmic.200401202

Source DB:  PubMed          Journal:  Proteomics        ISSN: 1615-9853            Impact factor:   3.984


  28 in total

1.  Personalized Medicine in the Age of Pharmacoproteomics: A Close up on India and Need for Social Science Engagement for Responsible Innovation in Post-Proteomic Biology.

Authors:  Panga Jaipal Reddy; Rekha Jain; Young-Ki Paik; Robin Downey; Adam S Ptolemy; Vural Ozdemir; Sanjeeva Srivastava
Journal:  Curr Pharmacogenomics Person Med       Date:  2011-03-01

2.  Transcriptomic and proteomic profile of Aspergillus fumigatus on exposure to artemisinin.

Authors:  Poonam Gautam; Santosh Kumar Upadhyay; Wazid Hassan; Taruna Madan; Ravi Sirdeshmukh; Curam Sreenivasacharlu Sundaram; Wasudev Namdeo Gade; Seemi Farhat Basir; Yogendra Singh; Puranam Usha Sarma
Journal:  Mycopathologia       Date:  2011-07-14       Impact factor: 2.574

3.  Investigation of molecular factors associated with malignant transformation of oligodendroglioma by proteomic study of a single case of rapid tumor progression.

Authors:  Chul-Kee Park; Jin Hyun Kim; Min Jeong Moon; Ji Hye Jung; Su-Young Lim; Sung-Hye Park; Jong-Hoon Kim; Dong Gyu Kim; Hee-Won Jung; Byung-Kyu Cho; Sun Ha Paek
Journal:  J Cancer Res Clin Oncol       Date:  2007-07-26       Impact factor: 4.553

4.  TROY interacts with Rho guanine nucleotide dissociation inhibitor α (RhoGDIα) to mediate Nogo-induced inhibition of neurite outgrowth.

Authors:  Yan Lu; Xiujie Liu; Jianfeng Zhou; Aijun Huang; Jiazhen Zhou; Cheng He
Journal:  J Biol Chem       Date:  2013-10-15       Impact factor: 5.157

5.  LC-MS/MS analysis of differentially expressed glioblastoma membrane proteome reveals altered calcium signaling and other protein groups of regulatory functions.

Authors:  Ravindra Varma Polisetty; Poonam Gautam; Rakesh Sharma; H C Harsha; Sudha C Nair; Manoj Kumar Gupta; Megha S Uppin; Sundaram Challa; Aneel Kumar Puligopu; Praveen Ankathi; Aniruddh K Purohit; Giriraj R Chandak; Akhilesh Pandey; Ravi Sirdeshmukh
Journal:  Mol Cell Proteomics       Date:  2012-01-04       Impact factor: 5.911

Review 6.  Application and implementation of selective tissue microdissection and proteomic profiling in neurological disease.

Authors:  Jay Jagannathan; Jie Li; Nicholas Szerlip; Alexander O Vortmeyer; Russell R Lonser; Edward H Oldfield; Zhengping Zhuang
Journal:  Neurosurgery       Date:  2009-01       Impact factor: 4.654

7.  Comprehensive characterization of glioblastoma tumor tissues for biomarker identification using mass spectrometry-based label-free quantitative proteomics.

Authors:  Maxime S Heroux; Marla A Chesnik; Brian D Halligan; Mona Al-Gizawiy; Jennifer M Connelly; Wade M Mueller; Scott D Rand; Elizabeth J Cochran; Peter S LaViolette; Mark G Malkin; Kathleen M Schmainda; Shama P Mirza
Journal:  Physiol Genomics       Date:  2014-05-06       Impact factor: 3.107

8.  Multifarious proteomic signatures and regional heterogeneity in glioblastomas.

Authors:  Chul-Kee Park; Ji Hye Jung; Sung-Hye Park; Hee-Won Jung; Byung-Kyu Cho
Journal:  J Neurooncol       Date:  2009-02-15       Impact factor: 4.130

9.  Immunohistochemical expression and mutation study of Prohibitin gene in Indian female breast cancer cases.

Authors:  Mohammad Zeeshan Najm; Shuaib Zaidi; Waseem Ahmad Siddiqui; Syed Akhtar Husain
Journal:  Med Oncol       Date:  2013-05-29       Impact factor: 3.064

10.  Manipulating prohibitin levels provides evidence for an in vivo role in androgen regulation of prostate tumours.

Authors:  D Alwyn Dart; Bradley Spencer-Dene; Simon C Gamble; Jonathan Waxman; Charlotte L Bevan
Journal:  Endocr Relat Cancer       Date:  2009-07-27       Impact factor: 5.678

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.